Seasonal Influenza Vaccines

  • Anthony E. Fiore
  • Carolyn B. Bridges
  • Nancy J. Cox
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 333)


Influenza vaccines are the mainstay of efforts to reduce the substantial health burden from seasonal influenza. Inactivated influenza vaccines have been available since the 1940s and are administered via intramuscular injection. Inactivated vaccines can be given to anyone six months of age or older. Live attenuated, cold-adapted influenza vaccines (LAIV) were developed in the 1960s but were not licensed in the United States until 2003, and are administered via nasal spray. Both vaccines are trivalent preparations grown in eggs and do not contain adjuvants. LAIV is licensed for use in the United States for healthy nonpregnant persons 2–49 years of age.

Influenza vaccination induces antibodies primarily against the major surface glycoproteins hemagglutinin (HA) and neuraminidase (NA); antibodies directed against the HA are most important for protection against illness. The immune response peaks at 2–4 weeks after one dose in primed individuals. In previously unvaccinated children <9 years of age, two doses of influenza vaccine are recommended, as some children in this age group have limited or no prior infections from circulating types and subtypes of seasonal influenza. These children require both an initial priming dose and a subsequent booster dose of vaccine to mount a protective antibody response.

The most common adverse events associated with inactivated vaccines are sore arm and redness at the injection site; systemic symptoms such as fever or malaise are less commonly reported. Guillian–Barré Syndrome (GBS) was identified among approximately 1 per 100,000 recipients of the 1976 swine influenza vaccine. The risk of influenza vaccine-associated GBS from seasonal influenza vaccine is thought to be at most approximately 1–2 cases per 1 million vaccinees, based on a few studies that have found an association; other studies have found no association.

The most common adverse events associated with LAIV are nasal congestion, headache, myalgias or fever. Studies of the safety of LAIV among young children suggest an increased risk of wheezing in some young children, and the vaccine is not recommended for children younger than 2 years old, ages 2-4 old with a history of recurrent wheezing or reactive airways disease, or older persons who have any medical condition that confers an increased risk of influenza-related complications.

The effectiveness of influenza vaccines is related predominantly to the age and immune competence of the vaccinee and the antigenic relatedness of vaccine strains to circulating strains. Vaccine effectiveness in preventing laboratory-confirmed influenza illness when the vaccine strains are well matched to circulating strains is 70–90% in randomized, placebo-controlled trials conducted among children and young healthy adults, but is lower among elderly or immunocompromised persons. In years with a suboptimal match, vaccine benefit is likely to be lower, although the vaccine can still provide substantial benefit, especially against more severe outcomes. Live, attenuated influenza vaccines have been most extensively studied among children, and have been shown to be more effective than inactivated vaccines in several randomized controlled trials among young children.

Influenza vaccination is recommended in the United States for all children six months or older, all adults 50 years or older, all persons with chronic medical conditions, and pregnant women, and contacts of these persons, including healthcare workers. The global disease burden of influenza is substantial, and the World Health Organization has indicated that member states should evaluate the cost-effectiveness of introducing influenza vaccination into national immunization programs. More research is needed to develop more effective seasonal influenza vaccines that provide long-lasting immunity and broad protection against strains that differ antigenically from vaccine viruses.


Influenza Virus Influenza Vaccine Influenza Vaccination Influenza Season Vaccine Adverse Event Reporting System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abramson JS, Neuzil KM, Tamblyn SE (2006) Annual universal influenza vaccination: ready or not? Clin Infect Dis 42:132–135PubMedCrossRefGoogle Scholar
  2. Ahmed AH et al. (1997) Effectiveness of influenza vaccine in reducing hospital admissions during the 1989–90 epidemic. Epidemiol Infect 118:27–33PubMedCrossRefGoogle Scholar
  3. Alexandrova GI et al. (1986) Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. Vaccine 4:114–118PubMedCrossRefGoogle Scholar
  4. Ali T et al. (2004) Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (Flumist). Clin Infect Dis 38:760–762PubMedCrossRefGoogle Scholar
  5. Allison MA et al. (2006) Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003–2004 season. J Pediatr 149:755–762PubMedCrossRefGoogle Scholar
  6. Anon (1944) A clinical evaluation of vaccination against influenza. JAMA 124:982–985Google Scholar
  7. Arden NH, Patriarca PA, Kendal AP (1986) Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA (eds) Options for the control of influenza. Alan R. Liss, New York, pp 155–168Google Scholar
  8. Ashkenazi S et al. (2006) Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25:870–879PubMedCrossRefGoogle Scholar
  9. Audicana MT et al. (2002) Allergic contact dermatitis from mercury antiseptics and derivatives: study protocol of tolerance to intramuscular injections of thimerosal. Am J Contact Dermat 13:3–9PubMedCrossRefGoogle Scholar
  10. Babcock HM, Merz LR, Fraser VJ (2006) Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol 27:266–270PubMedCrossRefGoogle Scholar
  11. Baez M, Palese P, Kilbourne ED (1980) Gene composition of high-yielding influenza vaccine strains obtained by recombination. J Infect Dis 141:362–365PubMedGoogle Scholar
  12. Barker WH (1986) Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970–78. Am J Public Health 76:761–765PubMedCrossRefGoogle Scholar
  13. Barry DW et al. (1976) Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am J Epidemiol 104:47–59PubMedGoogle Scholar
  14. Belshe RB, Gruber WC (2000) Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 19:S66–S71PubMedCrossRefGoogle Scholar
  15. Belshe RB, Mendelman PM (2003) Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent. Immunol Allergy Clin North Am 23:745–767PubMedCrossRefGoogle Scholar
  16. Belshe RB et al. (1998) The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 338:1405–1412PubMedCrossRefGoogle Scholar
  17. Belshe RB et al. (2000a) Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136:168–175CrossRefGoogle Scholar
  18. Belshe RB et al. (2000b) Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181:1133–1137CrossRefGoogle Scholar
  19. Belshe RB et al. (2004) Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin Infect Dis 39:920–927PubMedCrossRefGoogle Scholar
  20. Belshe RB et al. (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356:685–696PubMedCrossRefGoogle Scholar
  21. Bergen R et al. (2004) Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 23:138–144PubMedCrossRefGoogle Scholar
  22. Beyer WE et al. (1998) The plea against annual influenza vaccination? “The Hoskins’ Paradox” revisited. Vaccine 16:1929–1932PubMedCrossRefGoogle Scholar
  23. Bhat N et al. (2005) Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med 353:2559–2567PubMedCrossRefGoogle Scholar
  24. Block SL et al. (2008) Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 26:4940–6CrossRefGoogle Scholar
  25. Bridges CB et al. (2000) Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284:1655–1663PubMedCrossRefGoogle Scholar
  26. Bright RA et al. (2006) Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 295:891–894PubMedCrossRefGoogle Scholar
  27. Brokstad KA et al. (1995) Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 171:198–203PubMedGoogle Scholar
  28. Brooks WA et al. (2007) Human metapneumovirus infection among children, Bangladesh. Emerg Infect Dis 13:1611–1613Google Scholar
  29. Buonagurio DA et al. (2006) Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology 347:296–306PubMedCrossRefGoogle Scholar
  30. Carrat F, et al. (2008) Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 167:775–85PubMedCrossRefGoogle Scholar
  31. Carman WF et al. (2000) Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 355:93–97PubMedCrossRefGoogle Scholar
  32. Cate TR et al. (1977) Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence. J Infect Dis 136(Suppl):S450–S455PubMedGoogle Scholar
  33. Cate TR et al. (1983) Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines—1978. Rev Infect Dis 5:737–747PubMedGoogle Scholar
  34. CDC (1992) Outbreak of influenza A in a nursing home—New York, December 1991–January 1992. MMWR 41:129–131Google Scholar
  35. CDC (2007) Update: influenza activity—United States and Worldwide, May 20–September 17, 2007. MMWR 56:1001–1004Google Scholar
  36. Cha TA et al. (2000) Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 38:839–845PubMedGoogle Scholar
  37. Chen Z et al. (2006) Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (flumist). Virology 345:416–423PubMedCrossRefGoogle Scholar
  38. Choi K, Thacker SB (1982) Mortality during influenza epidemics in the United States, 1967–1978. Am J Public Health 72:1280–1283PubMedCrossRefGoogle Scholar
  39. Clover RD et al. (1991) Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis 163:300–304PubMedGoogle Scholar
  40. Coles FB, Balzano GJ, Morse DL (1992) An outbreak of influenza A (H3N2) in a well immunized nursing home population. J Am Geriatr Soc 40:589–592PubMedGoogle Scholar
  41. Colombo C et al. (2001) Influenza vaccine in healthy preschool children. Rev Epidemiol Sante Publique 49:157–162PubMedGoogle Scholar
  42. Connolly AM et al. (1993) What are the complications of influenza and can they be prevented? Experience from the 1989 epidemic of H3N2 influenza A in general practice. BMJ 306:1452–1454PubMedCrossRefGoogle Scholar
  43. Corey L et al. (1976) A nationwide outbreak of Reye’s syndrome. Its epidemiologic relationship to influenza B. Am J Med 61:615–625PubMedCrossRefGoogle Scholar
  44. Cox NJ, Bridges CB (2007) Inactivated and live attenuated influenza vaccines in young children—how do they compare? N Engl J Med 356:729–731PubMedCrossRefGoogle Scholar
  45. Cox NJ et al. (1985) Comparative studies of A/Leningrad/134/57 wild-type and 47-times passaged cold-adapted mutant influenza viruses: oligonucleotide mapping and RNA-RNA hybridization studies. J Gen Virol 66(Pt 8):1697–1704PubMedCrossRefGoogle Scholar
  46. Creighton C (1891) A History of epidemics in Britain, AD 664–1666. Cambridge University Press, New YorkGoogle Scholar
  47. Cunney RJ et al. (2000) An outbreak of influenza A in a neonatal intensive care unit. Infect Control Hosp Epidemiol 21:449–454PubMedCrossRefGoogle Scholar
  48. Davenport FM (1962) Current knowledge of influenza vaccine. JAMA 182:121–123Google Scholar
  49. Davies JR, Grilli EA (1989) Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 102:325–333PubMedCrossRefGoogle Scholar
  50. Deguchi Y, Takasugi Y, Tatara K (2000) Efficacy of influenza vaccine in the elderly in welfare nursing homes: reduction in risks of mortality and morbidity during an influenza A (H3N2) epidemic. J Med Microbiol 49:553–556PubMedGoogle Scholar
  51. Demicheli V et al. (2000) Prevention and early treatment of influenza in healthy adults. Vaccine 18:957–1030PubMedCrossRefGoogle Scholar
  52. Demicheli V et al. (2004) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev CD001269Google Scholar
  53. Dharan NJ et al. (2009) Infections with oseltamivir-resistant influenza A(H1N1) viruses in the United States. JAMA 301:1034–41PubMedCrossRefGoogle Scholar
  54. Dietzman DE et al. (1976) Acute myositis associated with influenza B infection. Pediatrics 57:255–258PubMedGoogle Scholar
  55. Doherty PC et al. (2006) Influenza and the challenge for immunology. Nat Immunol 7:449–455PubMedCrossRefGoogle Scholar
  56. Donabedian AM et al. (1988) A mutation in the PA protein gene of cold-adapted B/Ann Arbor/1/66 influenza virus associated with reversion of temperature sensitivity and attenuated virulence. Virology 163:444–451PubMedCrossRefGoogle Scholar
  57. Dowdle WR (1981) Influenza immunoprophylaxis after 30 years’ experience. In: Genetic variation among influenza viruses. Academic, New York, pp 525–534Google Scholar
  58. Dowdle WR et al. (1973) Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J 49:159–163PubMedCrossRefGoogle Scholar
  59. Edwards KM, Griffin MR (2006) Influenza vaccination of children: can it be accomplished? J Infect Dis 194:1027–1029PubMedCrossRefGoogle Scholar
  60. Edwards KM et al. (1994) A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 169:68–76PubMedGoogle Scholar
  61. el-Madhun AS et al. (1998) Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis 178:933–939PubMedCrossRefGoogle Scholar
  62. Elder AG et al. (1996) Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993–94 epidemic: results of serum testing and questionnaire. BMJ 313:1241–1242PubMedGoogle Scholar
  63. Englund JA et al. (2005) A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 115:1039–1047PubMedCrossRefGoogle Scholar
  64. Ennis FA et al. (1977) Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines. J Infect Dis 136(Suppl):S397–S406PubMedGoogle Scholar
  65. Esposito S et al. (2003) Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine 21:3162–3168PubMedCrossRefGoogle Scholar
  66. Fedson DS et al. (1993) Clinical effectiveness of influenza vaccination in Manitoba. JAMA 270:1956–1961PubMedCrossRefGoogle Scholar
  67. Fine AD et al. (2001) Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 32:1784–1791PubMedCrossRefGoogle Scholar
  68. Fiore AE et al. (2008) Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 57:1–60PubMedGoogle Scholar
  69. Fleming DM et al. (1995) Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989–90 using a general practice database. Epidemiol Infect 115:581–589PubMedCrossRefGoogle Scholar
  70. Fleming DM et al. (2006) Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 25:860–869PubMedCrossRefGoogle Scholar
  71. Foster DA et al. (1992) Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 136:296–307PubMedGoogle Scholar
  72. Fox JP et al. (1982a) Influenzavirus infections in Seattle families, 1975–1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol 116:212–227Google Scholar
  73. Fox JP et al. (1982b) Influenzavirus infections in Seattle families, 1975–1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 116:228–242Google Scholar
  74. Francis T (1945) The development of the 1943 vaccination study of the Commission on Influenza. Am J Hyg 42:1–11Google Scholar
  75. Francis T, Salk JE, Brace WM (1946) The protective effect of vaccination against epidemic influenza B. JAMA 131:275–278Google Scholar
  76. Freeman DW, Barno A (1959) Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 78:1172–1175PubMedGoogle Scholar
  77. Frey S et al. (2003) Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 21:4234–4237PubMedCrossRefGoogle Scholar
  78. Fukuda K, Kieny MP (2006) Different approaches to influenza vaccination. N Engl J Med 355:2586–2587PubMedCrossRefGoogle Scholar
  79. Fukuda K, Thompson WW, Cox NJ (2001) To the editor: (vaccinating Japanese schoolchildren against influenza). N Engl J Med 344:1946–1947PubMedCrossRefGoogle Scholar
  80. Gaglani MJ et al. (2004) Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000–2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 158:65–73PubMedCrossRefGoogle Scholar
  81. Gerhard W (2001) The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 260:171–190PubMedGoogle Scholar
  82. Ghendon YZ et al. (1984) Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants. Infect Immun 44:730–733PubMedGoogle Scholar
  83. Ghendon YZ, Kaira AN, Elshina GA (2006) The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. Epidemiol Infect 134:71–78PubMedCrossRefGoogle Scholar
  84. Glaser CA et al. (2002) Medical care capacity for influenza outbreaks, Los Angeles. Emerg Infect Dis 8:569–574PubMedGoogle Scholar
  85. Glezen WP (2006) Herd protection against influenza. J Clin Virol 37:237–243PubMedCrossRefGoogle Scholar
  86. Glezen WP, Couch RB (1978) Interpandemic influenza in the Houston area, 1974–76. N Engl J Med 298:587–592PubMedGoogle Scholar
  87. Govaert TM et al. (1994) The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 272:1661–1665PubMedCrossRefGoogle Scholar
  88. Green DM (2002) Advances in the management of guillain-barre syndrome. Curr Neurol Neurosci Rep 2:541–548PubMedCrossRefGoogle Scholar
  89. Gregg MB (1980) The epidemiology of influenza in humans. Ann N Y Acad Sci 353:45–53PubMedCrossRefGoogle Scholar
  90. Gross PA et al. (1995) The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 123:518–527PubMedGoogle Scholar
  91. Gross PA et al. (1997) Time to earliest peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab Immunol 4:491–492PubMedGoogle Scholar
  92. Gruber WC et al. (1996) Evaluation of live attenuated influenza vaccines in children 6–18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J Infect Dis 173:1313–1319PubMedGoogle Scholar
  93. Gubareva LV et al. (1998) Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 178:1257–1262PubMedCrossRefGoogle Scholar
  94. Gubareva LV et al. (2001) Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183:523–531PubMedCrossRefGoogle Scholar
  95. Hak E et al. (2002a) Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 35:370–377CrossRefGoogle Scholar
  96. Hak E et al. (2002b) Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Commun Health 56:951–955CrossRefGoogle Scholar
  97. Hak E et al. (2005) Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med 165:274–280PubMedCrossRefGoogle Scholar
  98. Hall CE, Cooney MK, Fox JP (1973) The Seattle virus watch. IV. Comparative epidemiologic observations of infections with influenza A and B viruses, 1965–1969, in families with young children. Am J Epidemiol 98:365–380PubMedGoogle Scholar
  99. Halloran ME, Longini IM, Jr. (2006) Public health. Community studies for vaccinating schoolchildren against influenza. Science 311:615–616PubMedCrossRefGoogle Scholar
  100. Halperin SA et al. (2002) Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20:1240–1247PubMedCrossRefGoogle Scholar
  101. Harper SA et al. (2009) Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical guidelines of the Infectious Diseases Society of America 48:1003–32Google Scholar
  102. Harris JW (1919) Influenza occurring in pregnant women: a statistical study of thirteen hundred and fifty cases. JAMA 72:978–980Google Scholar
  103. Hauge SH et al. (2009) Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 15:155–62PubMedCrossRefGoogle Scholar
  104. Hayward AC et al. (2006) Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 333:1241PubMedCrossRefGoogle Scholar
  105. Heikkinen T, Thint M, Chonmaitree T (1999) Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 340:260–264PubMedCrossRefGoogle Scholar
  106. Heinonen OP et al. (1973) Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy. Int J Epidemiol 2:229–235PubMedCrossRefGoogle Scholar
  107. Helms CM et al. (2005) Strengthening the nation’s influenza vaccination system: a National Vaccine Advisory Committee assessment. Am J Prev Med 29:221–226PubMedCrossRefGoogle Scholar
  108. Herrera GA et al. (2007) Influenza vaccine effectiveness among 50–64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003–2004. Vaccine 25:154–160PubMedCrossRefGoogle Scholar
  109. Hoberman A et al. (2003) Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 290:1608–1616PubMedCrossRefGoogle Scholar
  110. Hobson D et al. (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond.) 70:767–777Google Scholar
  111. Hoelscher MA et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367:475–481PubMedCrossRefGoogle Scholar
  112. Hoskins TW et al. (1973) Controlled trial of inactivated influenza vaccine containing the a-Hong Kong strain during an outbreak of influenza due to the a-England-42–72 strain. Lancet 2:116–120PubMedCrossRefGoogle Scholar
  113. Hoskins TW et al. (1979) Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s Hospital. Lancet 1:33–35PubMedCrossRefGoogle Scholar
  114. Hurwitz ES et al. (1981) Guillain–Barre syndrome and the 1978–1979 influenza vaccine. N Engl J Med 304:1557–1561PubMedGoogle Scholar
  115. Hurwitz ES et al. (2000a) Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 284:1677–1682CrossRefGoogle Scholar
  116. Hurwitz ES et al. (2000b) Studies of the 1996–1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. J Infect Dis 182:1218–1221CrossRefGoogle Scholar
  117. Inouye S, Kramer MH (2001) To the editor: (vaccinating Japanese schoolchildren against influenza). N Engl J Med 344:1946PubMedCrossRefGoogle Scholar
  118. Irving WL et al. (2000) Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study. BJOG 107:1282–1289PubMedCrossRefGoogle Scholar
  119. Izurieta HS et al. (2005) Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 294:2720–2725PubMedCrossRefGoogle Scholar
  120. Jackson LA et al. (1999) Safety of a trivalent live attenuated intranasal influenza vaccine, flumist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 17:1905–1909PubMedCrossRefGoogle Scholar
  121. Jackson LA et al. (2006) Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35:337–344PubMedCrossRefGoogle Scholar
  122. Jefferson TO et al. (2007) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev CD001269Google Scholar
  123. Johnson PR, Jr. et al. (1985) Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol 17:325–335PubMedCrossRefGoogle Scholar
  124. Johnson PR et al. (1986) Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 154:121–127PubMedGoogle Scholar
  125. Jordan R et al. (2006) Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine 24:1047–1062PubMedCrossRefGoogle Scholar
  126. Juurlink DN et al. (2006) Guillain–Barre syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 166:2217–2221PubMedCrossRefGoogle Scholar
  127. Kaplan JE et al. (1982) Guillain–Barre syndrome in the United States, 1979–1980 and 1980–1981. Lack of an association with influenza vaccination. JAMA 248:698–700PubMedCrossRefGoogle Scholar
  128. Keitel WA et al. (1997) Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 15:1114–1122PubMedCrossRefGoogle Scholar
  129. Keitel WA et al. (2006) Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 166:1121–1127PubMedCrossRefGoogle Scholar
  130. Keren R et al. (2005) Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. JAMA 294:2188–2194PubMedCrossRefGoogle Scholar
  131. Kilbourne ED, Murphy JS (1960) Genetic studies of influenza viruses. I. Viral morphology and growth capacity as exchangeable genetic traits. Rapid in-ovo adaptation of early passage Asian strain isolates by combination with PRS. J Exp Med 111:387–406PubMedCrossRefGoogle Scholar
  132. Kilbourne ED et al. (1968) Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 2:281–288PubMedGoogle Scholar
  133. Kim HW et al. (1979) Influenza A and B virus infection in infants and young children during the years 1957–1976. Am J Epidemiol 109:464–479PubMedGoogle Scholar
  134. King JC et al. (2000) Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 181:725–728PubMedCrossRefGoogle Scholar
  135. King JC, Jr. et al. (2001) Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 20:1124–1131PubMedCrossRefGoogle Scholar
  136. King JC, Jr. et al. (2006) Effectiveness of school-based influenza vaccination. N Engl J Med 355:2523–2532PubMedCrossRefGoogle Scholar
  137. Kiso M et al. (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759–765PubMedCrossRefGoogle Scholar
  138. Kistner O et al. (1999) A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production. Wien Klin Wochenschr 111:207–214PubMedGoogle Scholar
  139. Kramarz P et al. (2009) Use of oseltamivir in 12 European countires between 2002 and 2007–lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) virusesGoogle Scholar
  140. Kwong JC et al. (2006) The effect of universal influenza immunization on vaccination rates in Ontario. Health Rep 17:31–40PubMedGoogle Scholar
  141. Kwong JC, Rosella LC, Johansen H (2007) Trends in influenza vaccination in Canada, 1996/1997 to 2005. Health Rep 18:9–19PubMedGoogle Scholar
  142. Kwong JC et al. (2008) The effect of universal influenza immunization on mortality and health care use. PLoS Med 5:e211PubMedCrossRefGoogle Scholar
  143. LaMontagne Jr et al. (1983) Summary of clinical trials of inactivated influenza vaccine – 1978. Rev Infect Dis 5:723–736Google Scholar
  144. Lasky T et al. (1998) The Guillain Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 339:1797–1802PubMedCrossRefGoogle Scholar
  145. Lester RT et al. (2003) Use of, effectiveness of, and attitudes regarding influenza vaccine among house staff. Infect Control Hosp Epidemiol 24:839–844PubMedCrossRefGoogle Scholar
  146. LoGrippo GA (1960) Investigations of the use of beta propiolactone in virus inactivation. Ann NY Acad Sci 83:578–594PubMedCrossRefGoogle Scholar
  147. Lui KJ, Kendal AP (1987) Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 77:712–716PubMedCrossRefGoogle Scholar
  148. Maassab HF (1967) Adaptation and growth characteristics of influenza virus at 25°C. Nature 213:612–614PubMedCrossRefGoogle Scholar
  149. Maassab HF (1969) Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol 102:728–732PubMedGoogle Scholar
  150. Maassab HF et al. (1982) Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 146:780–790PubMedGoogle Scholar
  151. Mair M et al. (2006) Universal influenza vaccination: the time to act is now. Biosecur Bioterror 4:20–40PubMedCrossRefGoogle Scholar
  152. Mak TK et al. (2008) Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis 8:44–52PubMedCrossRefGoogle Scholar
  153. MedImmune (2008) Flumist (package insert). MedImmune, Gaithersburg (see
  154. Meijer A. et al. (2009) Oseltamivir-resistant influenza virus, Europe, 2007-08 season. Emerg Infect Dis Available from
  155. Meiklejohn G, Hall H (1987) Unusual outbreak of influenza A in a Wyoming nursing home. J Am Geriatr Soc 35:742–746PubMedGoogle Scholar
  156. Monto AS et al. (1970) Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 122:16–25PubMedGoogle Scholar
  157. Monto AS et al. (2000) Clinical signs and symptoms predicting influenza infection. Arch Intern Med 160:3243–3247PubMedCrossRefGoogle Scholar
  158. Monto AS, Kioumehr F (1975) The Tecumseh study of respiratory illness. IX. Occurrence of influenza in the community, 1966–1971. Am J Epidemiol 102:553–563PubMedGoogle Scholar
  159. Monto AS, Hornbuckle K, Ohmit SE (2001) Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 154:155–160PubMedCrossRefGoogle Scholar
  160. Morens DM, Rash VM (1995) Lessons from a nursing home outbreak of influenza A. Infect Control Hosp Epidemiol 16:275–280PubMedCrossRefGoogle Scholar
  161. Moritz A et al. (1980) Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus. II. Evaluation in adult volunteers. J Infect Dis 142:857–860Google Scholar
  162. Morris JA et al. (1966) Immunity to influenza to antibody levels. N Engl J Med 274:527–535PubMedCrossRefGoogle Scholar
  163. Mullooly JP et al. (1994) Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 121:947–952PubMedGoogle Scholar
  164. Neuzil KM et al. (1998) Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 148:1094–1102PubMedGoogle Scholar
  165. Neuzil KM et al. (2001) Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 20:733–740PubMedGoogle Scholar
  166. Neuzil KM, Hohlbein C, Zhu Y (2002) Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 156:986–991PubMedGoogle Scholar
  167. Neuzil KM et al. (2003) Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine. Clin Infect Dis 36:169–174PubMedCrossRefGoogle Scholar
  168. Neuzil KM, Jackson LA, Nelson J (2006) Immunogenicity and reactogenicity of one versus two doses of trivalent inactivated influenza vaccine in vaccine-naive 5–8-year-old children. J Infect DisGoogle Scholar
  169. Nichol KL et al. (1995) The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 333:889–893PubMedCrossRefGoogle Scholar
  170. Nichol KL, Wuorenma J, von Sternberg T (1998) Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158:1769–1776PubMedCrossRefGoogle Scholar
  171. Nichol KL et al. (1999) Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282:137–144PubMedCrossRefGoogle Scholar
  172. Nichol KL et al. (2007) Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 357:1373–1381PubMedCrossRefGoogle Scholar
  173. Ohmit SE, Monto AS (1995) Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol 24:1240–1248PubMedCrossRefGoogle Scholar
  174. Ohmit SE, Arden NH, Monto AS (1999) Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. J Am Geriatr Soc 47:165–171PubMedGoogle Scholar
  175. Ohmit SE et al. (2006) Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 355:2513–2522PubMedCrossRefGoogle Scholar
  176. Ohmit SE et al. (2008) Prevention of symptomatic seasonal influenza in 2005-06 by inactivated and live attenuated vaccines. J Infect Dis 198:312–7PubMedCrossRefGoogle Scholar
  177. Orenstein WA, Bernier RH, Hinman AR (1988) Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 10:212–241PubMedGoogle Scholar
  178. Orenstein WA et al. (2007) Financing immunization of adults in the United States. Clin Pharmacol Ther 82:764–768PubMedCrossRefGoogle Scholar
  179. Oshitani H et al. (2000) Influenza vaccination levels and influenza-like illness in long-term-care facilities for elderly people in Niigata, Japan, during an influenza A (H3N2) epidemic. Infect Control Hosp Epidemiol 21:728–730PubMedCrossRefGoogle Scholar
  180. Oya A, Nerome K (1986) Experiences with mass vaccination of young age groups with inactivated vaccines. In: Kendal AP, Patriarca PA (eds) Options for the control of influenza. Alan R. Liss, New York, pp. 183–192Google Scholar
  181. Palache AM, Brands R, van Scharrenburg GJ (1997) Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 176(Suppl 1):S20–S23PubMedCrossRefGoogle Scholar
  182. Palache AM et al. (1999) Safety, reactogenicity and immunogenicity of Madin Darby canine kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev Biol Stand 98:115–125PubMedGoogle Scholar
  183. Patriarca PA et al. (1985) Efficacy of influenza vaccine in nursing homes reduction in illness and complications during an Influenza A (H3N2) epidemic. JAMA 253:1136–1139PubMedCrossRefGoogle Scholar
  184. Percheson PB et al. (1999) A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line. Dev Biol Stand 98:127–132PubMedGoogle Scholar
  185. Perrotta DM, Decker M, Glezen WP (1985) Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. Am J Epidemiol 122:468–476PubMedGoogle Scholar
  186. Piedra PA et al. (2005a) Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23:1540–1548CrossRefGoogle Scholar
  187. Piedra PA et al. (2005b) Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116:e397–e407CrossRefGoogle Scholar
  188. Piedra PA et al. (2007) Trivalent live attenuated intranasal influenza vaccine administered during the 2003–2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 120:e553–e564PubMedCrossRefGoogle Scholar
  189. Poehling KA et al. (2006) The underrecognized burden of influenza in young children. N Engl J Med 355:31–40PubMedCrossRefGoogle Scholar
  190. Potter J et al. (1997) Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 175:1–6PubMedGoogle Scholar
  191. Prevots DR, Sutter RW (1997) Assessment of Guillain–Barre syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis 175:S151–S155PubMedGoogle Scholar
  192. Puig-Barbera J et al. (1997) Reduction in hospital admissions for pneumonia in non-institutionalised elderly people as a result of influenza vaccination: a case–control study in Spain. J Epidemiol Community Health 51:526–530PubMedCrossRefGoogle Scholar
  193. Quinnan GV et al. (1983) Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev Infect Dis 5:748–757PubMedGoogle Scholar
  194. Reichert TA et al. (2001a) To the editor: (vaccinating Japanese schoolchildren against influenza). N Engl J Med 344:1947–1948CrossRefGoogle Scholar
  195. Reichert TA et al. (2001b) The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 344:889–896CrossRefGoogle Scholar
  196. Ritzwoller DP et al. (2005) Effectiveness of the 2003–2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 116:153–159PubMedCrossRefGoogle Scholar
  197. Rivetti D et al. (2006) Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 3:CD004876PubMedGoogle Scholar
  198. Rocha E et al. (1991) Antigenic and genetic variation in influenza A (H1N1) virus isolates recovered from a persistently infected immunodeficient child. J Virol 65:2340–2350PubMedGoogle Scholar
  199. Ropper AH (1992) The Guillain–Barre syndrome. N Engl J Med 326:1130–1136PubMedGoogle Scholar
  200. Rudenko LG et al. (1993) Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 168:881–887PubMedGoogle Scholar
  201. Russell KL et al. (2005) Effectiveness of the 2003–2004 influenza vaccine among US military basic trainees: a year of suboptimal match between vaccine and circulating strain. Vaccine 23:1981–1985PubMedCrossRefGoogle Scholar
  202. Ruuskanen O et al. (1989) Acute otitis media and respiratory virus infections. Pediatr Infect Dis J 8:94–99PubMedGoogle Scholar
  203. Saito R et al. (2002) The effectiveness of influenza vaccine against influenza a (H3N2) virus infections in nursing homes in Niigata, Japan, during the 1998–1999 and 1999–2000 seasons. Infect Control Hosp Epidemiol 23:82–86PubMedCrossRefGoogle Scholar
  204. Salgado CD et al. (2004) Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians. Infect Control Hosp Epidemiol 25:923–928PubMedCrossRefGoogle Scholar
  205. Salk JE, Menke WJ, Francis T (1945) A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza. Am J Hyg 42:57–93Google Scholar
  206. Sato M et al. (2005) Antibody response to influenza vaccination in nursing home residents and healthcare workers during four successive seasons in Niigata, Japan. Infect Control Hosp Epidemiol 26:859–866PubMedCrossRefGoogle Scholar
  207. Saxen H, Virtanen M (1999) Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 18:779–783PubMedCrossRefGoogle Scholar
  208. Schanzer DL, Langley JM, Tam TW (2007) Influenza-attributed hospitalization rates among pregnant women in Canada 1994–2000. J Obstet Gynaecol Can 29:622–629PubMedGoogle Scholar
  209. Schoenbaum SC, Weinstein L (1979) Respiratory infection in pregnancy. Clin Obstet Gynecol 22:293–300PubMedCrossRefGoogle Scholar
  210. Schonberger LB et al. (1979) Guillain–Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol 110:105–123PubMedGoogle Scholar
  211. Schwartz B et al. (2006) Universal influenza vaccination in the United States: are we ready? Report of a meeting. J Infect Dis 194(Suppl 2):S147–S154PubMedCrossRefGoogle Scholar
  212. Shek LP, Lee BW (2003) Epidemiology and seasonality of respiratory tract virus infections in the tropics. Paediatr Respir Rev 4:105–111PubMedCrossRefGoogle Scholar
  213. Shope RE (1931) Swine influenza. I. Experimental transmission and pathology. J Exp Med 54:349–359PubMedCrossRefGoogle Scholar
  214. Shuler CM et al. (2007) Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003–2004. Pediatrics 119:e587–e595PubMedCrossRefGoogle Scholar
  215. Simon NM, Rovner RN, Berlin BS (1970) Acute myoglobinuria associated with type A2 (Hong Kong) influenza. JAMA 212:1704–1705PubMedCrossRefGoogle Scholar
  216. Simonsen L et al. (1997) The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 87:1944–1950PubMedCrossRefGoogle Scholar
  217. Simonsen L et al. (2000) The impact of influenza epidemics on hospitalizations. J Infect Dis 181:831–837PubMedCrossRefGoogle Scholar
  218. Simonsen L, Viboud C, Taylor RJ (2007) Effectiveness of influenza vaccination. N Engl J Med 357:2729–2730PubMedGoogle Scholar
  219. Smith W, Andrewes CH, Laidlaw PP (1933) A virus obtained from influenza patients. Lancet 2:66–68CrossRefGoogle Scholar
  220. Smith NM et al. (2006a) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55:1–42Google Scholar
  221. Smith S et al. (2006b) Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev CD004879Google Scholar
  222. Smits AJ et al. (2002) Clinical effectiveness of conventional influenza vaccination in asthmatic children. Epidemiol Infect 128:205–211PubMedCrossRefGoogle Scholar
  223. Snyder MH et al. (1988) Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 62:488–495PubMedGoogle Scholar
  224. Staynor K et al. (1994) Influenza A outbreak in a nursing home: the value of early diagnosis and the use of amantadine hydrochloride. Can J Infect Control 9:109–111PubMedGoogle Scholar
  225. Stokes J et al. (1937) Results of immunization by means of active virus of human influenza. J Clin Invest 16:237–243PubMedCrossRefGoogle Scholar
  226. Strickler JK et al. (2007) Influenza vaccine effectiveness among US military basic trainees, 2005–06 season. Emerg Infect Dis 13:617–619PubMedCrossRefGoogle Scholar
  227. Sugaya N et al. (1994) Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA 272:1122–1126PubMedCrossRefGoogle Scholar
  228. Surtees R, DeSousa C (2006) Influenza virus associated encephalopathy. Arch Dis Child 91:455–456PubMedCrossRefGoogle Scholar
  229. Szilagyi P et al. (2008) Influenza vaccine effectiveness among children 6 to 59 months of age during two influenza seasons: a case-cohort study. Arch Med (in press)Google Scholar
  230. Talbot TR et al. (2005) Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol 26:494–500PubMedCrossRefGoogle Scholar
  231. Tam JS et al. (2007) Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 26:619–628PubMedCrossRefGoogle Scholar
  232. Tasker SA et al. (1999) Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann. Intern Med 131:430–433PubMedGoogle Scholar
  233. Thomas RE et al. (2006) Influenza vaccination for health-care workers who work with elderly people in institutions: a systematic review. Lancet Infect Dis 6:273–279PubMedCrossRefGoogle Scholar
  234. Thompson T (1852) Annals of influenza or epidemic catarrhal fever in Great Britain from 1510 to 1837. Sydenham Society, LondonGoogle Scholar
  235. Thompson WW et al. (2003) Mortality associated with influenza and RSV. JAMA 289:179–186PubMedCrossRefGoogle Scholar
  236. Thompson WW et al. (2004) Influenza-associated hospitalizations in the United States. JAMA 292:1333–1340PubMedCrossRefGoogle Scholar
  237. Togashi T, Matsuzono Y, Narita M (2000) Epidemiology of influenza-associated encephalitis-encephalopathy in Hokkaido, the northernmost island of Japan. Pediatr Int 42:192–196PubMedCrossRefGoogle Scholar
  238. Treanor JD (2007) Influenza—the goal of control. N Engl J Med 357:1439–1441PubMedCrossRefGoogle Scholar
  239. Treanor JJ et al. (1999) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18:899–906PubMedCrossRefGoogle Scholar
  240. Vesikari T et al. (2006a) Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 118:2298–2312CrossRefGoogle Scholar
  241. Vesikari T et al. (2006b) A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 25:590–595CrossRefGoogle Scholar
  242. Vu T et al. (2002) A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20:1831–1836PubMedCrossRefGoogle Scholar
  243. Wang Z, et al. (2009) Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 301:1066–9CrossRefGoogle Scholar
  244. Weingarten S et al. (1988) Do hospital employees benefit from the influenza vaccine? A placebo-controlled clinical trial. J Gen Intern Med 3:32–37PubMedCrossRefGoogle Scholar
  245. Weycker D et al. (2005) Population-wide benefits of routine vaccination of children against influenza. Vaccine 23:1284–1293PubMedCrossRefGoogle Scholar
  246. WHO (2005) H5N1 avian influenza: first steps towards development of a human vaccine. Wkly Epidemiol Rec 80:277–278Google Scholar
  247. WHO (2008) Meeting of the immunization strategic advisory group of experts, November 2007—conclusions and recommendations. Wkly Epidemiol Rec 83:1–16Google Scholar
  248. Widelock D, Csizmas L, Klein S (1963) Influenza, pregnancy, and fetal outcome. Public Health Rep 78:1–11PubMedCrossRefGoogle Scholar
  249. Wilde JA et al. (1999) Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 281:908–913PubMedCrossRefGoogle Scholar
  250. Williams MS, Wood JM (1993) A brief history of inactivated influenza virus vaccines. In: Hannoun C et al (eds) Elsevier, Amsterdam, pp 169–171Google Scholar
  251. Willison HJ, Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591–2625PubMedCrossRefGoogle Scholar
  252. Wright PF et al. (1977) Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 136(Suppl):S731–S741PubMedGoogle Scholar
  253. Wright PF et al. (1982) Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis 146:71–79PubMedGoogle Scholar
  254. Wright PF et al. (1983) Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children—a multicentered evaluation of dosage and safety. Rev Infect Dis 5:758–764PubMedGoogle Scholar
  255. Yamazaki T, Suzuki T, Yamamoto K (2001) To the editor: (vaccinating Japanese schoolchildren against influenza). N Engl J Med 344:1947PubMedGoogle Scholar
  256. Yang L et al. (2008) Synchrony of clinical and laboratory surveillance for influenza in Hong Kong. PLoS ONE 3:e1399PubMedCrossRefGoogle Scholar
  257. Zaman K, et al. (2008) Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 359:1555–64PubMedCrossRefGoogle Scholar
  258. Zangwill KM et al. (2001) Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J 20:740–746PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Anthony E. Fiore
    • 1
  • Carolyn B. Bridges
    • 1
  • Nancy J. Cox
    • 1
  1. 1.Centers for Disease Control and PreventionNE-AtlantaUSA

Personalised recommendations